LSBio
Paraplegin / SPG7 Antibody (clone OTI3H10)

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY SPG7 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-SPG7.

Paraplegin / SPG7 Antibody (clone OTI3H10)

Primary AntibodyLSBio Guarantee
Antibody:Mouse Monoclonal
Applications:Flow Cytometry, Immunofluorescence, Immunohistochemistry (general), Western Blot
Reactivity:Human
Format:Liquid
See all Human Paraplegin / SPG7 antibodies →
$443.00each
Catalog Number: LS-C175082-100

For bulk orders or custom formulations:

Request a Quote

Overview

Description
SPG7 antibody LS-C175082 is an unconjugated mouse monoclonal antibody to human SPG7 (Paraplegin). Validated for Flow, IF and WB. Cited in 1 publication.
Application
FC, IF, IHC, WB
Reactivity
Hu
Intended Use
Research Use Only
Guarantees
This antibody carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Monoclonal Antibodies
Alternative Names
Cell adhesion regulator | Cell matrix adhesion regulator | Paraplegin | PGN | SPG5C | SPG7 | Spastic paraplegia 7 protein | CAR | CMAR
Recommended Dilution: FC
1:100
Recommended Dilution: IF/ICC
1:100
Recommended Dilution: WB
1:2000
UniProt Number
Q9UQ90
SwissProt
Q9UQ90

Target

Target
Human Paraplegin / SPG7
Antigen Species
Human
Epitope
Human Paraplegin / SPG7
Gene Name
SPG7

Antibody

Host Species
Mouse
Clonality
Monoclonal
Clone
OTI3H10
Isotype
IgG1

Immunogen

Immunogen
Human recombinant protein fragment corresponding to amino acids 300-573 of human SPG7 (NP_003110) produced in E. coli.
Immunogen Type
Recombinant Protein Fragment

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
PBS, pH 7.3, 0.02% Sodium Azide, 50% Glycerol, 1% BSA
Concentration
1 mg/mL
Volume
100 Microliter
Preservative
Yes
Purification Method
Protein A/G Affinity

Storage & Handling

Storage Conditions
Store at -20°C. Avoid freeze-thaw cycles.
Recommended Storage Buffer
PBS
Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia. Irene Sambri, Filomena Massa, Francesca Gullo, Simone Meneghini, Laura Cassina, Michela Carraro, Giorgia Dina, Angelo Quattrini, Lorenzo Patanella, Annamaria Carissimo, Antonella Iuliano, Filippo Santorelli, Franca Codazzi, Fabio Grohovaz, Paolo Bernardi, Andrea Becchetti, Giorgio Casari. EBioMedicine. 2020 November;61:103050. PubMed: 33045469 PMC: PMC7553352

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.